1. Medtech Insight
  2. >>Business
  3. >>Investor Eye

Investor Eye: Endeavour Vision Highlights Humanity Of Medtech, Invests In Unmet Needs

 
• By Barnaby Pickering

Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.

Investor Eye Fetaure Image

Minneapolis-based venture capital firm Endeavor Vision has created the Endeavor Medtech Growth II LP fund to invest in what it describes as “transformative health care technologies,” following the same strategy as its previous fund. 

Endeavour Medtech Growth II LP closed with a total investment of $375m, on 22 April. So far, the fund has already invested in eight companies for more than $100m, including;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Investor Eye

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.